Trial Profile
A Pilot Study to Assess the Efficacy of Linagliptin as an Adjunct in Schizophrenia Patients
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 Oct 2021
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 14 Aug 2018 Status changed from suspended to discontinued.
- 23 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2018.
- 23 Sep 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2018.